These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18495540)

  • 1. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
    Gonzalez VD; Falconer K; Michaëlsson J; Moll M; Reichard O; Alaeus A; Sandberg JK
    Clin Immunol; 2008 Jul; 128(1):46-56. PubMed ID: 18495540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
    Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
    Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
    Lee S; Watson MW; Flexman JP; Cheng W; Hammond T; Price P
    J Med Virol; 2010 Apr; 82(4):568-74. PubMed ID: 20166183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
    Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
    J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype.
    Bhardwaj S; Ahmad F; Wedemeyer H; Cornberg M; Schulze Zur Wiesch J; van Lunzen J; Sarin SK; Schmidt RE; Meyer-Olson D
    Virol J; 2016 Apr; 13():67. PubMed ID: 27091211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment.
    Dessouki O; Kamiya Y; Nagahama H; Tanaka M; Suzu S; Sasaki Y; Okada S
    Biochem Biophys Res Commun; 2010 Mar; 393(2):331-7. PubMed ID: 20138830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
    Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
    Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.
    Bozzano F; Picciotto A; Costa P; Marras F; Fazio V; Hirsch I; Olive D; Moretta L; De Maria A
    Eur J Immunol; 2011 Oct; 41(10):2905-14. PubMed ID: 21695691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
    Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
    Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alteration of CD100 expression on natural killer cells in chronic patients with hepatitis C virus before and after initiation of antiviral treatment].
    He Y; Li B; Zhou Y; Zhang Y; Guo Y; Ji G; Fan C; Jia Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):856-60. PubMed ID: 25108441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD56
    Judge CJ; Kostadinova L; Sherman KE; Butt AA; Falck-Ytter Y; Funderburg NT; Landay AL; Lederman MM; Sieg SF; Sandberg JK; Anthony DD
    J Leukoc Biol; 2017 Jul; 102(1):171-184. PubMed ID: 28400540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection.
    Oliviero B; Mele D; Degasperi E; Aghemo A; Cremonesi E; Rumi MG; Tinelli C; Varchetta S; Mantovani S; Colombo M; Mondelli MU
    J Hepatol; 2013 Jul; 59(1):38-44. PubMed ID: 23499727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic immune activation in the T cell compartment of HCV/HIV-1 co-infected patients.
    Sandberg JK; Falconer K; Gonzalez VD
    Virulence; 2010; 1(3):177-9. PubMed ID: 21178437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity.
    Hu PF; Hultin LE; Hultin P; Hausner MA; Hirji K; Jewett A; Bonavida B; Detels R; Giorgi JV
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):331-40. PubMed ID: 7552495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use.
    Hotho DM; Kreefft K; Groothuismink ZM; Janssen HL; de Knegt RJ; Boonstra A
    Antiviral Res; 2013 Mar; 97(3):347-55. PubMed ID: 23291200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
    Bräu N
    Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of NKG2A with treatment for chronic hepatitis C virus infection.
    Harrison RJ; Ettorre A; Little AM; Khakoo SI
    Clin Exp Immunol; 2010 Aug; 161(2):306-14. PubMed ID: 20550548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection.
    Reiberger T; Rasoul-Rockenschaub S; Rieger A; Ferenci P; Gangl A; Peck-Radosavljevic M
    Eur J Clin Invest; 2008 Jun; 38(6):421-9. PubMed ID: 18489402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future.
    Cammà C; Petta S
    J Hepatol; 2009 Apr; 50(4):648-51. PubMed ID: 19231012
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.